這是描述信息
Search
Submit
Cancel
Nanjing RegeneCore Biotech Co.,Ltd
Nanjing RegeneCore Biotech Co.,Ltd

REGENECORE is an innovative start-up company under the YOUNGY Group, advocating science and culture, paying attention to the growth of employees and enterprises, and maintaining human health.

Nanjing RegeneCore Biotech Co.,Ltd
Nanjing RegeneCore Biotech Co.,Ltd

Mature and complete nanobody humanization technology platform, antibody immunogenicity detection technology platform, and high-throughput nanobody screening technology platform.

這是描述信息

Nanjing RegeneCore Biotech Co.,Ltd

Nanjing RegeneCore Biotech Co.,Ltd is established in the Biomedical Valley of National Nanjing Jiangbei New Area, with a research and office base of nearly 4000 square meters. It is one of the first research and development institutions in the field of nanobodies in China. The company's international scientific consulting expert team has rich experience in the research and development of cell therapy products and clinical applications, providing strong guarantees for the precise positioning and success rate of research and development products. The company has mature and leading nanobody screening technology, and conducts in-depth development in multiple application fields based on this technology.

more
company

NEWS

Nanjing RegeneCore Announces New Breakthrough in Brain-Penetrating Drug Delivery Technology

Nanjing RegeneCore Announces New Breakthrough in Brain-Penetrating Drug Delivery Technology

The blood-brain barrier (BBB) strictly regulates the passage of substances into and out of the central nervous system (CNS), playing a crucial role in preventing harmful substances from entering the brain from the bloodstream. However, it also poses a significant challenge by restricting most drugs from reaching the brain parenchyma, severely limiting the treatment of CNS disorders.
Nanjing Rongjiekang RC1416 dual antibody has obtained 2 clinical trial licenses again

Nanjing Rongjiekang RC1416 dual antibody has obtained 2 clinical trial licenses again

Recently, Nanjing RegeneCore Biotechnology Co., Ltd.'s RC1416 project has consecutively obtained Investigational New Drug (IND) approvals from the National Medical Products Administration's Center for Drug Evaluation (CDE) for indications of atopic dermatitis (AD) and chronic obstructive pulmonary disease (COPD). The expansion of these indications has further diversified the clinical application scenarios of RC1416 injection, providing better treatment options for more patients.
YOUNGY GROUP: Racing to New Frontiers and Scaling New Heights in Life Sciences

YOUNGY GROUP: Racing to New Frontiers and Scaling New Heights in Life Sciences

Recently, Nanjing RegeneCore Biotech Co., Ltd. issued a recruitment notice for patients with moderate to severe asthma, drawing widespread attention. It turns out that RC1416 injection—China's first domestically developed autoimmune bispecific nanobody drug independently researched by RegeneCore—is currently undergoing clinical trials at dozens of renowned hospitals nationwide. Demonstrating significant advantages in efficacy, safety, and druggability, this bispecific antibody therapy holds promise as a breakthrough treatment for patients suffering from moderate to severe asthma.

 

Platforms

High throughput nanobody screening technology platform, nanobody humanization technology platform, antibody immunogenicity detection technology platform, biomacromolecule analysis technology platform, antibody drug CMC process development technology platform

TEL:

025-58608860

Address: Room 07 Building 16 Treehouse, No. 73, Tanmi Road, Jiangbei New District, Nanjing

Enterprise email:rjk@regenecore.com

 

這是描述信息

WeChat cooperative consultation

You are the th visitor